Get started
Virtus LifeSci Biotech Clinical Trials ETFVV

Virtus LifeSci Biotech Clinical Trials ETF

17.61USDR
−0.32−1.78%
At close at May 13, 20:05 GMT
USD
No trades
See on Supercharts
Overview
Analysis
Holdings News Ideas Discussions Technicals Seasonals Options

Key stats


Assets under management (AUM)
‪11.71 M‬ USD
Fund flows (1Y)
‪4.70 M‬ USD
Dividend yield (indicated)
1.33%
Discount/Premium to NAV
0.5%
Shares outstanding
‪650.00 K‬
Expense ratio
0.79%

About Virtus LifeSci Biotech Clinical Trials ETF


Issuer
Virtus Investment Partners, Inc.
Brand
Virtus
Home page
virtus.com
Inception date
Dec 16, 2014
Structure
Open-Ended Fund
Index tracked
LifeSci Biotechnology Clinical Trials Index
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Virtus ETF Advisers LLC
Distributor
VP Distributors LLC
BBC focuses on biotech companies with lead drugs that are still in various phases of clinical trials and not yet approved marketing. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. It excludes companies with a lead drug candidate thats still in preclinical testing or research stage, prior to entering into human clinical trials. Also excluded are the following 12 distinct sub-industries: Animal Health, Diversified Healthcare, Investment Management, Healthcare Services, Non-Healthcare, Large Pharmaceuticals, Specialty Pharmaceuticals, Medical Devices, Vaccines, Nutraceuticals, OTC Healthcare, or Tools. As such, investors looking for broad biotech exposure, won't find it in BBC. The Index Committee utilizes various public data sources to select portfolio holdings, including, SEC filings, public documents from the U.S. FDA, company press releases and official corporate websites.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Life sciences tools & services
Strategy
Equal
Geography
U.S.
Weighting scheme
Equal
Selection criteria
Proprietary

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance——————
NAV total return——————

What's in the fund


As of May 12, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.05%
Health Technology97.88%
Commercial Services1.17%
Bonds, Cash & Other0.95%
Cash0.95%
Stock breakdown by region
87%11%0.5%
North America87.46%
Europe11.99%
Asia0.55%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Symbol
Assets
Symbol
Assets
S
Soleno Therapeutics IncSLNO
1.88%
X
Xeris Biopharma Holdings, Inc.XERS
1.66%
A
Akero Therapeutics, Inc.AKRO
1.63%
L
Liquidia CorporationLQDA
1.63%
S
Summit Therapeutics IncSMMT
1.61%
A
AnaptysBio, Inc.ANAB
1.52%
M
Mineralys Therapeutics, Inc.MLYS
1.40%
A
Arcutis Biotherapeutics IncARQT
1.34%
C
CureVac N.V.CVAC
1.29%
P
Protagonist Therapeutics, Inc.PTGX
1.28%
Top 10 weight15.23%
125 total holdings

Dividends


Dec '23
Dec '24
‪0.00‬
‪0.06‬
‪0.12‬
‪0.18‬
‪0.24‬
Dividend amount
Dividend payout history
Ex-date
Record date
Pay date
Amount
Frequency
Dec 20, 2024
Dec 20, 2024
Dec 27, 2024
0.239
Annual
Dec 20, 2023
Dec 21, 2023
Dec 29, 2023
0.082
Annual

Assets under management (AUM)



Fund Flows